RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

In vivo gene editing therapies offer the potential to treat the root causes of many genetic
diseases. Realizing the promise of therapeutic in vivo gene editing requires the ability to …

The expanding applications of nonviral genomic medicines in the lung remain restricted by
delivery challenges. Here, leveraging a high-throughput platform, we synthesize and screen …

Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …

Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

In situ tissue regeneration harnesses the body's regenerative potential to control cell
functions for tissue repair. The design of biomaterials for in situ tissue engineering requires …

We designed a unique nanocapsule for efficient single CRISPR-Cas9 capsuling,
noninvasive brain delivery and tumor cell targeting, demonstrating an effective and safe …

Lipid nanoparticles (LNPs) are a potent delivery technology that have made it possible for
the recent clinical breakthroughs in mRNA therapeutics and vaccines. A key challenge to the …

CRISPR–Cas gene editing and messenger RNA-based protein replacement therapy hold
tremendous potential to effectively treat disease-causing mutations with diverse cellular …

In 2021, mRNA vaccines against COVID-19 were approved by the Food and Drug
Administration. mRNA vaccines are important for preventing severe COVID-19 and returning …